MVA-CCHF

MVA-CCHF is a viral vector vaccine candidate developed for the prevention of Crimean-Congo haemorrhagic fever (CCHF), a widespread tick-borne viral disease with high fatality rates. The vaccine utilizes the Modified Vaccinia virus Ankara (MVA) platform, a highly attenuated and non-replicating orthopoxvirus, to express the glycoprotein precursor (GPC) of the CCHF virus. This approach is designed to induce both robust neutralizing antibodies and T-cell mediated immune responses against the virus. The development is a collaborative effort involving the UK Health Security Agency (UKHSA) and the University of Oxford's Jenner Institute. As of 2024, the vaccine is undergoing a first-in-human, dose-escalation Phase I clinical trial sponsored by the University Hospital Southampton NHS Foundation Trust to evaluate its safety, reactogenicity, and immunogenicity in healthy adult volunteers.

Other names

Modified Vaccinia virus Ankara-Crimean-Congo haemorrhagic fever vaccine